Resonant Capital Advisors LLC Decreases Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Resonant Capital Advisors LLC decreased its position in Becton, Dickinson and Company (NYSE:BDX) by 11.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,043 shares of the medical instruments supplier’s stock after selling 1,179 shares during the quarter. Resonant Capital Advisors LLC’s holdings in Becton, Dickinson and Company were worth $2,205,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the company. Householder Group Estate & Retirement Specialist LLC acquired a new position in shares of Becton, Dickinson and Company during the 3rd quarter worth about $25,000. OFI Invest Asset Management acquired a new position in shares of Becton, Dickinson and Company in the 3rd quarter valued at $25,000. Fortitude Family Office LLC acquired a new position in shares of Becton, Dickinson and Company in the 4th quarter valued at $35,000. Optimum Investment Advisors grew its position in shares of Becton, Dickinson and Company by 35.6% in the 3rd quarter. Optimum Investment Advisors now owns 160 shares of the medical instruments supplier’s stock valued at $41,000 after buying an additional 42 shares during the last quarter. Finally, Advisors Asset Management Inc. acquired a new stake in Becton, Dickinson and Company during the 1st quarter worth $40,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

BDX has been the topic of several research reports. Raymond James raised their price objective on Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Barclays raised their price target on Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a research note on Monday, February 5th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $280.00.

Becton, Dickinson and Company Stock Performance

Shares of NYSE:BDX traded up $1.02 on Friday, reaching $234.17. The company’s stock had a trading volume of 711,513 shares, compared to its average volume of 1,397,451. Becton, Dickinson and Company has a 52-week low of $229.40 and a 52-week high of $287.32. The stock has a market capitalization of $67.65 billion, a P/E ratio of 55.43, a PEG ratio of 1.92 and a beta of 0.43. The stock’s 50-day moving average is $240.19 and its two-hundred day moving average is $242.58. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.08 and a quick ratio of 0.64.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, February 1st. The medical instruments supplier reported $2.68 EPS for the quarter, beating the consensus estimate of $2.39 by $0.29. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. The firm had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.73 billion. During the same period in the prior year, the business earned $2.98 EPS. The firm’s revenue was up 2.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 12.94 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 29th. Shareholders of record on Friday, March 8th were paid a $0.95 dividend. The ex-dividend date of this dividend was Thursday, March 7th. This represents a $3.80 annualized dividend and a yield of 1.62%. Becton, Dickinson and Company’s dividend payout ratio is currently 90.05%.

Insiders Place Their Bets

In other news, SVP Thomas J. Spoerel sold 282 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the sale, the senior vice president now owns 2,276 shares of the company’s stock, valued at $542,348.04. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.31% of the stock is owned by insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.